Skip to main content
AmigoFish

Episode 168: Pancreatic Cancer Series, Pt. 3 – Borderline Resectable and Locally Advanced Disease

From The Fellow on Call: The Heme/Onc Podcast ·

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

This week we continue our Pancreatic Cancer series with the two middle categories of non-metastatic disease: borderline resectable and locally advanced. Using the case of a 61-year-old woman with a pancreatic body mass abutting the superior mesenteric artery, we walk through the vascular definitions that separate resectable, borderline resectable, and locally advanced disease, then trace how multi-agent chemotherapy borrowed from the metastatic setting became the neoadjuvant backbone. We dig into the newest challenger to mFOLFIRINOX, PAXG in the CASSANDRA trial, and the still-contested role of radiation, from Alliance A021501 to PREOPANC-2. Along the way, we cover why restaging CT can understate response, how LAP07 reframed consolidative chemoradiation in locally advanced disease, and what to offer patients who are not candidates for intensive therapy. As always, if you haven't heard the earlier episodes in this series, start there first.

As always, if you haven't listened to parts 1 and 2 (episodes 165 and 166, respectively)

This episode is sponsored by Primum! As questions of oncology experts (including pancreatic cancer) free! To learn more and to sign up for your free account, visit Primum.co/fellows

** Want to review the show notes for this episode and others? Check out our website.

Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Youtube

Back to The Fellow on Call: The Heme/Onc Podcast · Report a problem